Login / Signup

Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma.

Dan LuTong LuRong ShiLeonid GibianskyPriya AgarwalColby S ShemeshRandall C DereUzor OgbuJamie HirataPascal ChanuSandhya GirishJin Yan JinChunze LiDale Miles
Published in: Pharmaceutical research (2020)
In patients with NHL, bodyweight-based dosing is adequate, and no further dose adjustment is recommended for the heavier subgroup (100-146 kg). In addition, no dose adjustments are recommended for other subgroups based on intrinsic/extrinsic factors evaluated.
Keyphrases
  • study protocol